Embedded Files
Lunit has partnered with Daiichi Sankyo to deploy its AI-driven SCOPE pathology platform across two undisclosed oncology R&D programs, aiming to generate quantitative tissue data to inform patient selection and trial design.
Why It Matters To Oncology
▪ AI-powered pathology tools like SCOPE IO and SCOPE universal IHC promise more consistent, scalable insights from tumor samples.
▪ Quantitative data can refine patient stratification and support trial efficiency for multiple cancer types.
The Financials
▪ Deal terms were not disclosed.
▪ Lunit is in active talks with ~15 of the top 20 global pharma companies, signaling growing commercial traction.
What They're Saying
▪ Lunit cites AstraZeneca as an example of deep, ongoing partnerships using SCOPE beyond single studies.
▪ "AI-derived pathology insights must prove analytical and clinical value to expand across pharma pipelines," per Lunit.
What's Next
▪ Focus will be on demonstrating reproducible, operationally meaningful data outputs that drive clinical decisions.
▪ Wider adoption hinges on showing robust, actionable results in real-world drug development.
Page updated
Report abuse